Your browser doesn't support javascript.
The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy's Cancer Centre.
Russell, Beth; Moss, Charlotte; Tsotra, Eirini; Gousis, Charalampos; Josephs, Debra; Enting, Deborah; Karampera, Christina; Khan, Muhammad; Roca, Jose; Sita-Lumsden, Ailsa; Owczarczyk, Kasia; Wylie, Harriet; Haire, Anna; Smith, Daniel; Zaki, Kamarul; Swampillai, Angela; Lei, Mary; Manik, Vishal; Michalarea, Vasiliki; Kristeleit, Rebecca; Mera, Anca; Sawyer, Elinor; Flanders, Lucy; De Francesco, Irene; Papa, Sophie; Ross, Paul; Spicer, James; Dann, Bill; Jogia, Vikash; Shaunak, Nisha; Kristeleit, Hartmut; Rigg, Anne; Montes, Ana; Van Hemelrijck, Mieke; Dolly, Saoirse.
  • Russell B; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London SE1 9RT, UK.
  • Moss C; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London SE1 9RT, UK.
  • Tsotra E; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Gousis C; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Josephs D; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Enting D; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Karampera C; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Khan M; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Roca J; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Sita-Lumsden A; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Owczarczyk K; Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Wylie H; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London SE1 9RT, UK.
  • Haire A; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London SE1 9RT, UK.
  • Smith D; Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Zaki K; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Swampillai A; Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Lei M; Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Manik V; Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Michalarea V; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Kristeleit R; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Mera A; Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Sawyer E; Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Flanders L; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • De Francesco I; Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Papa S; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Ross P; Immunoengineering Group, King's College London, London SE1 9RT, UK.
  • Spicer J; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Dann B; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Jogia V; Pharmacy, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Shaunak N; Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Kristeleit H; Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Rigg A; Pharmacy, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Montes A; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Van Hemelrijck M; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
  • Dolly S; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London SE1 9RT, UK.
Cancers (Basel) ; 14(2)2022 Jan 06.
Article in English | MEDLINE | ID: covidwho-1613623
ABSTRACT

BACKGROUND:

This study aimed to assess the outcome of cancer patients undergoing systemic anti-cancer treatment (SACT) at our centre to help inform future clinical decision-making around SACT during the COVID-19 pandemic.

METHODS:

Patients receiving at least one episode of SACT for solid tumours at Guy's Cancer Centre between 1 March and 31 May 2020 and the same period in 2019 were included in the study. Data were collected on demographics, tumour type/stage, treatment type (chemotherapy, immunotherapy, biological-targeted) and SARS-CoV2 infection.

RESULTS:

A total of 2120 patients received SACT in 2020, compared to 2449 in 2019 (13% decrease). From 2019 to 2020, there was an increase in stage IV disease (62% vs. 72%), decrease in chemotherapy (42% vs. 34%), increase in immunotherapy (6% vs. 10%), but similar rates of biologically targeted treatments (37% vs. 38%). There was a significant increase in 1st and 2nd line treatments in 2020 (68% vs. 81%; p < 0.0001) and reduction in 3rd and subsequent lines (26% vs. 15%; p = 0.004) compared to 2019. Of the 2020 cohort, 2% patients developed SARS-CoV2 infections.

CONCLUSIONS:

These real-world data from a tertiary Cancer Centre suggest that despite the challenges faced due to the COVID-19 pandemic, SACT was able to be continued without any significant effects on the mortality of solid-tumour patients. There was a low rate (2%) of SARS-CoV-2 infection which is comparable to the 1.4%-point prevalence in our total cancer population.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: Cancers14020266

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: Cancers14020266